A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of bacterial acute infection in mice

International Immunopharmacology

Volumn 3, Issue 2, 2003, Pages 247-256

  Vallespi, Maribel G ^a   Alvarez Obregon J C ^a   Rodriguez Alonso, I ^a   Montero, T ^b   Garay, H ^a   Reyes, O ^a   Arana M J ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Hospital Naval   (Cuba)

Author keywords

Anti LPS factor; Immunomodulation; Innate immunity; Th1 Th2 response

Indexed keywords

ANTIINFECTIVE AGENT; CYSTEINYLHISTIDYLTYROSYLARGINYLISOLEUCYLLYSYLPROLYLTHREONYLPHENYLALANYLARGI NYLARGINYLLEUCYLLYSYLTRYPTOPHYLLYSYLTYROSYLLYSYLGLYCYLLYSYLPHENYLALANYLTRYPTOPHY LCYSTEINE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL PERITONITIS; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION REGULATION; GRAM NEGATIVE BACTERIUM; HISTOPATHOLOGY; HOST RESISTANCE; IMMUNOMODULATION; LIVER; LIVER HISTOLOGY; MESSENGER RNA SYNTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPLEEN; SURVIVAL; TISSUE INJURY;

EID: 0037317595     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00277-1     Document Type: Article

References (34)

1. Lederer J.A., Rodrick M.L., Mannick J.A. The effects of injury on the adaptive immune response. Shock. 11:1999;153-159.
2. Risuke K., Shigeru M., Hidemitsu H., Kouji M. The molecular pathogenesis of endotoxic shock and organ failure. Mol. Med. Today. 1999;123-132.
3. Döcke W.D., Randow F., Syrbe U., Krausch D., Asadullah K., Volk H.D.et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3:1997;678-681.
4. Vallespi M., Glaria L.A., Reyes O., Garay H.E., Ferrero J., Araña M.J. A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases. Clin. Diagn. Lab. Immunol. 7:2000;669-675.
5. Menrrifield R.B. Solid phase peptide synthesis. J. Am. Chem. Soc. 85:1963;2149-2154.
6. Dentener M.A., Greve J.W., Maessen J.G., Buurman W.A. Role of TNF in the enhanced sensitivity of mice to endotoxin after exposure to lead. Immunopharmacol. Immunotoxicol. 11:1989;231-334.
7. Reiner S.L., Zheng S., Corry D.B., Locksley R.M. Constructing polycompetitor cDNA for quantitative PCR. J. Immunol. Methods. 165:1993;37-46.
8. Svetic A., Finkelman F.D., Jian Y.C. Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J. Immunol. 147:1991;2391-2397.
9. Johnston C.A., Greisman S.E. Mechanism of endotoxina tolerance. Hinshaw L.B. Handbook of endotoxin. vol. 2:1985;359-391 Elsevier, New York.
10. Ried C., Wahl C., Miethke T., Wellnhofer G., Landgraf C., Schneider-Mergener J.et al. High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor. J. Biol. Chem. 271:1996;28120-28127.
11. Battafarano R.J., Dahlberg P.S., Ratz C.A. Peptides derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced TNF secretion in vitro. Surgery. 118:1995;318-324.
12. Mosmann T.R., Subash S. The expanding universe of T-cell subsets: Th1-Th2 and more. Immunol. Today. 17:1996;138-146.
13. Trinchieri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol. Today. 14:1993;335-337.
14. Ottenhoff T.H., Kumararatne D., Casanova J.L. Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Immunol. Today. 19:1998;491-494.
15. Ulett G.C., Ketheesan N., Hirst R.G. Cytokine gene expression in innately susceptible Balb/c mice relatively resistant C57BL/6 mice during infection with virule Burkholderia pseudomallei. Infect. Immun. 68:2000;2034-2042.
16. Tracey K.J., Fong Y., Hesse D.G. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:1987;662-664.
17. Alpert G., Baldwin G., Thompson C. Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. Crit. Care Med. 22:1992;494-500.
18. Jin H., Yang R., Marsters S. Protection against endotoxin shock by bactericidal/permeability-increasing protein in rats. J. Clin. Invest. 95:1995;1947-1952.
19. Robert I.R., Donghui S., Child A.H., Wainwright N.R., Levin J. Limulus anti-lipopolysaccharide factor prevents mortality late in the course of endotoxemia. J. Infect. Dis. 177:1998;388-394.
20. Lavigne L.M., Schopf L.R., Chung C.L., Maylor R., Sypek J.P. The role of recombinant murine IL-12 and IFN-γ in the pathogenesis of a murine systemic Candida albicans infection. J. Immunol. 160:1998;284-292.
21. Biron C., Gazzinelli R.T. Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating diseases outcome. Curr. Opin. Immunol. 7:1995;485-494.
22. Kawakami K., Tohyama Q., Xie Q., Saito A. Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: effect of IL-12. Infect. Immun. 65:1997;1307-1312.
23. Kashino S.S., Fazioli R.A., Cafalli-Favati C., Meloni-Bruneri L.H., Vaz C.A., Burger E.et al. Resistance to Paracoccidioides brasiliensis infection is linked to a preferential Th1 immune response, whereas susceptibility is associated with absence of IFN-γ production. J. Interferon Cytokine. 20:2000;89-97.
24. Flynn J.L., Goldstein M.M., Triebold K.J., Sypek J., Wolf S., Bloom B.R. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155:1995;2515-2524.
25. Goebel A., Kavanagh E., Lyons A., Saporoschetz I.B., Soberg C., Lederer J.A.et al. Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann. Surg. 231:2000;253-261.
26. Lauw F.N., ten Hove T., Dekkers P.E., de Jonge E., van Deventer S.J., van Der Poll T. Reduced Th1, but not Th2, cytokine production by lymphocytes after in vivo exposure of healthy subjects to endotoxin. Infect. Immun. 68:2000;1014-1018.
27. Ayala A., Deol Z.K., Lehman D.L., Herdon C.D., Chaudry I.H. Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-γ release while increasing IL-4/IL-10 production. J. Surg. Res. 56:1994;579-585.
28. Martineau L., Shek P.N. Changes in circulating lymphocyte subpopulations and mitogen-stimulated response in a rat infusion model of intra-abdominal. Infect. Crit. Care Med. 28:2000;2515-2521.
29. Tzianabos A.O., Russell P.R., Onderdonk A.B., Ginbson F.C. III, Cywes C., Chan M.et al. IL-2 mediates protection against abscess formation in an experimental model of sepsis. J. Immunol. 163:1999;893-897.
30. Lang A. IL-2 crucial for dendritic-cell activation. Trends Immunol. 22:2001;596-597.
31. Zurawski G., Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today. 15:1994;19-26.
32. Matsukawa A., Hogaboam C.M., Lukacs N.W., Lincoln P.M., Evanoff H.L., Strieter R.M.et al. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J. Immunol. 164:2000;2738-2744.
33. Minty A., Chalon P., Derocq J.M., Dumont X., Guillemot J.C., Kaghad M.et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune response. Nature. 62:1993;248-250.
34. Jankovic D., Liu Z., Gause W.C. Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol. 22:2001;450-457.